Dispositions (Tables)

3 Months Ended

Mar. 31, 2017

Discontinued Operations and Disposal Groups [Abstract]

Major Classes of Assets Sold and Gain Recognized

The following table presents the consideration received, major classes of assets sold and the gain recognized on the sale of the Non-Core ACC Products:

	(in thousands)
Sale price:
Cash	$	263,807
Contingent purchase price from sale of business	65,700
Total sale price	329,507
Assets:
Inventory	2,184
Intangibles	5,210
Goodwill	33,812
Total assets sold	41,206
Gain on sale of business	$	288,301

The following table presents key financial results of the Hemostasis Business included in “Loss from discontinued operations, net of tax” for the three months ended March 31, 2016:

	Three Months Ended March 31,
	2016
Net product revenues	$	62
Operating expenses:
Cost of product revenue	2,293
Research and development	146
Selling, general and administrative	693
Total operating expenses	3,132
Income (loss) from operations	(3,070		)
Gain from sale of business	1,004
Other expense, net	(39		)
Income (loss) from discontinued operations before income taxes	(2,105		)
Benefit for income taxes	—
Loss from discontinued operations, net of tax	$	(2,105	)